CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+14.98%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$787M
AUM Growth
+$787M
(+53%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
29.03%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
459
New
34
Increased
332
Reduced
39
Closed
19
Top Buys
| 1 |
Microsoft
MSFT
|
$18.2M |
| 2 |
NVIDIA
NVDA
|
$11.9M |
| 3 |
Netflix
NFLX
|
$9.94M |
| 4 |
Amazon
AMZN
|
$7.89M |
| 5 |
Meta Platforms (Facebook)
META
|
$7.84M |
Top Sells
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.64M |
| 2 |
Alibaba
BABA
|
$2.59M |
| 3 |
XYZ
Block, Inc.
XYZ
|
$2.4M |
| 4 |
Intel
INTC
|
$2.07M |
| 5 |
Coca-Cola
KO
|
$1.91M |
Sector Composition
| 1 | Technology | 37.36% |
| 2 | Healthcare | 29.98% |
| 3 | Consumer Discretionary | 13.6% |
| 4 | Communication Services | 8.97% |
| 5 | Financials | 3.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Bank of America
BAC
$373B
| $542K | 0.07% |
+14,300
| New | +$542K |
|
177
Arvinas
ARVN
$580M
| $539K | 0.07% |
13,064
+6,694
| +105% | +$276K |
|
178
Beam Therapeutics
BEAM
$1.65B
| $526K | 0.07% |
15,919
+6,252
| +65% | +$207K |
|
179
Intellia Therapeutics
NTLA
$1.22B
| $508K | 0.06% |
18,474
+8,119
| +78% | +$223K |
|
180
Rhythm Pharmaceuticals
RYTM
$6.92B
| $501K | 0.06% |
11,561
+4,724
| +69% | +$205K |
|
|
ALPN
181
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $501K | 0.06% |
12,630
+5,907
| +88% | +$234K |
|
182
Merus
MRUS
$5.01B
| $500K | 0.06% |
11,113
+4,432
| +66% | +$200K |
|
183
Vericel Corp
VCEL
$1.75B
| $483K | 0.06% |
9,284
+3,763
| +68% | +$196K |
|
184
Guardant Health
GH
$8.29B
| $483K | 0.06% |
23,406
+9,754
| +71% | +$201K |
|
185
Apogee Therapeutics
APGE
$2.26B
| $475K | 0.06% |
7,155
+1,600
| +29% | +$106K |
|
186
AutoZone
AZO
$69.9B
| $473K | 0.06% |
+150
| New | +$473K |
|
187
Kymera Therapeutics
KYMR
$2.91B
| $472K | 0.06% |
11,753
+5,330
| +83% | +$214K |
|
188
Rocket Pharmaceuticals
RCKT
$350M
| $468K | 0.06% |
17,365
+6,941
| +67% | +$187K |
|
189
Automatic Data Processing
ADP
$121B
| $465K | 0.06% |
1,853
+1,032
| +126% | +$259K |
|
190
Keros Therapeutics
KROS
$638M
| $458K | 0.06% |
6,916
+3,456
| +100% | +$229K |
|
191
Gildan
GIL
$7.81B
| $454K | 0.06% |
12,179
-17,100
| -58% | -$638K |
|
192
Thermo Fisher Scientific
TMO
$184B
| $451K | 0.06% |
+776
| New | +$451K |
|
193
Dyne Therapeutics
DYN
$1.92B
| $442K | 0.06% |
15,573
+8,474
| +119% | +$241K |
|
194
Accenture
ACN
$160B
| $436K | 0.06% |
+1,259
| New | +$436K |
|
195
Vera Therapeutics
VERA
$1.44B
| $436K | 0.06% |
10,117
+4,974
| +97% | +$214K |
|
196
Recursion Pharmaceuticals
RXRX
$2.02B
| $435K | 0.06% |
43,656
+19,565
| +81% | +$195K |
|
197
Immunocore
IMCR
$1.63B
| $430K | 0.05% |
6,621
+2,721
| +70% | +$177K |
|
198
PTC Therapeutics
PTCT
$4.16B
| $429K | 0.05% |
14,752
+6,025
| +69% | +$175K |
|
199
Mondelez International
MDLZ
$80B
| $427K | 0.05% |
6,073
+3,366
| +124% | +$237K |
|
200
Sana Biotechnology
SANA
$721M
| $424K | 0.05% |
42,400
+19,600
| +86% | +$196K |
|